Finanzen von Corvus Pharmaceuticals Inc (CRVS)CRVSCorvus Pharmaceuticals Inc

Evaluating the bottom line, Corvus Pharmaceuticals, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -35.43%, provide a clear picture of how effectively CRVS converts its operational activities into shareholder value.

In the context of the broader market, CRVS competes directly with industry leaders such as MNKD and MLTX. With a market capitalization of $1.25B, it holds a significant position in the sector. When comparing efficiency, CRVS's gross margin of N/A stands against MNKD's 69.00% and MLTX's N/A. Such benchmarking helps identify whether Corvus Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Corvus has shown substantial growth with a 1-year change of +149.74%. Despite recent losses, the company has a strong current ratio of 16.16, indicating good liquidity to cover its liabilities.